Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Imaging of castration-resistant prostrate cancer: development of imaging response biomarkers.

Morisson C, Jeraj R, Liu G.

Curr Opin Urol. 2013 May;23(3):230-6. doi: 10.1097/MOU.0b013e32835e9edc. Review.

PMID:
23422587
2.

[EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].

Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, van der Kwast T, Wiegel T, Zattoni F, Heidenreich A.

Actas Urol Esp. 2011 Nov-Dec;35(10):565-79. doi: 10.1016/j.acuro.2011.03.011. Epub 2011 Jul 14. Spanish.

PMID:
21757258
3.

Novel imaging techniques reshape the landscape in high-risk prostate cancers.

Lecouvet FE, Lhommel R, Pasoglou V, Larbi A, Jamar F, Tombal B.

Curr Opin Urol. 2013 Jul;23(4):323-30. doi: 10.1097/MOU.0b013e328361d451. Review.

PMID:
23619580
4.

[Treatment of prostate cancer].

Romics I.

Orv Hetil. 2010 Apr 4;151(14):580-3. doi: 10.1556/OH.2010.28810. Hungarian. No abstract available.

PMID:
20332076
5.

Choice of first-line treatment for metastatic prostate cancer.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):51. No abstract available.

PMID:
23444511
6.

Developing imaging strategies for castration resistant prostate cancer.

Fox JJ, Morris MJ, Larson SM, Schöder H, Scher HI.

Acta Oncol. 2011 Jun;50 Suppl 1:39-48. doi: 10.3109/0284186X.2011.572914.

7.

[Castration resistant prostate cancer 2011].

Miller K.

Aktuelle Urol. 2011 Mar;42(2):95-102. doi: 10.1055/s-0031-1271399. Epub 2011 Mar 24. Review. German.

PMID:
21437832
8.

Supplemental value of diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) technique to whole-body magnetic resonance imaging in detection of bone metastases from thyroid cancer.

Sakurai Y, Kawai H, Iwano S, Ito S, Ogawa H, Naganawa S.

J Med Imaging Radiat Oncol. 2013 Jun;57(3):297-305. doi: 10.1111/1754-9485.12020. Epub 2012 Dec 28.

PMID:
23721138
9.

Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy.

Takenaka D, Ohno Y, Matsumoto K, Aoyama N, Onishi Y, Koyama H, Nogami M, Yoshikawa T, Matsumoto S, Sugimura K.

J Magn Reson Imaging. 2009 Aug;30(2):298-308. doi: 10.1002/jmri.21858.

PMID:
19629984
10.

Lessons from in-vivo models of castration-resistant prostate cancer.

Lin D, Gout PW, Wang Y.

Curr Opin Urol. 2013 May;23(3):214-9. doi: 10.1097/MOU.0b013e32835e9f07.

PMID:
23385975
11.

First-line treatment of metastatic prostate cancer. Androgen suppression for symptomatic disease.

[No authors listed]

Prescrire Int. 2013 Feb;22(135):48-51. Review.

PMID:
23444510
13.

Using surrogate biomarkers to predict clinical benefit in men with castration-resistant prostate cancer: an update and review of the literature.

Armstrong AJ, Febbo PG.

Oncologist. 2009 Aug;14(8):816-27. doi: 10.1634/theoncologist.2009-0043. Epub 2009 Aug 14. Review.

14.

Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group.

Lecouvet FE, Talbot JN, Messiou C, Bourguet P, Liu Y, de Souza NM; EORTC Imaging Group.

Eur J Cancer. 2014 Oct;50(15):2519-31. doi: 10.1016/j.ejca.2014.07.002. Epub 2014 Aug 16. Review.

15.

Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.

Climent MA, Piulats JM, Sánchez-Hernández A, Arranz JÁ, Cassinello J, García-Donas J, González del Alba A, León-Mateos L, Mellado B, Méndez-Vidal MJ, Pérez-Valderrama B; Spanish Oncology Genitourinary Group.

Crit Rev Oncol Hematol. 2012 Sep;83(3):341-52. doi: 10.1016/j.critrevonc.2012.01.002. Epub 2012 Jan 29.

PMID:
22285697
16.

Comparison of FDG-PET/CT and bone scintigraphy for detection of bone metastases in breast cancer.

Hahn S, Heusner T, Kümmel S, Köninger A, Nagarajah J, Müller S, Boy C, Forsting M, Bockisch A, Antoch G, Stahl A.

Acta Radiol. 2011 Nov 1;52(9):1009-14. doi: 10.1258/ar.2011.100507. Epub 2011 Oct 3.

PMID:
21969709
17.

[Choice of the imaging technique for the diagnosis of bone metastases].

Genovese EA, Mallardo V, Rosati I, Prisco MR, Fontanarosa A, Della Vecchia N, D'Agosto G, Santagata M, Basile A.

Recenti Prog Med. 2013 Jul-Aug;104(7-8):361-6. doi: 10.1701/1315.14576. Review. Italian.

PMID:
24042408
18.

Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma.

Mosavi F, Johansson S, Sandberg DT, Turesson I, Sörensen J, Ahlström H.

AJR Am J Roentgenol. 2012 Nov;199(5):1114-20. doi: 10.2214/AJR.11.8351.

PMID:
23096187
19.

Serum bone turnover markers (PINP and ICTP) for the early detection of bone metastases in patients with prostate cancer: a longitudinal approach.

Koopmans N, de Jong IJ, Breeuwsma AJ, van der Veer E.

J Urol. 2007 Sep;178(3 Pt 1):849-53; discussion 853; quiz 1129. Epub 2007 Jul 16.

PMID:
17631330
20.

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.

Sharifi N.

Expert Opin Investig Drugs. 2010 Jul;19(7):837-46. doi: 10.1517/13543784.2010.494178. Review.

PMID:
20524793
Items per page

Supplemental Content

Write to the Help Desk